Stay updated on INSIGHT 2: Tepotinib+Osimertinib in MET+ NSCLC Clinical Trial

Sign up to get notified when there's something new on the INSIGHT 2: Tepotinib+Osimertinib in MET+ NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the INSIGHT 2: Tepotinib+Osimertinib in MET+ NSCLC Clinical Trial page

  1. Check
    2 days ago
    No Change Detected
  2. Check
    9 days ago
    Change Detected
    Summary
    Napoli, Italy was replaced with Naples, Italy in the location listings, and revision tags were updated to v3.5.0 (added) and v3.4.3 (removed).
    Difference
    0.0%
    Check dated 2026-03-21T00:44:54.000Z thumbnail image
  3. Check
    16 days ago
    No Change Detected
  4. Check
    24 days ago
    Change Detected
    Summary
    Revision note updated from v3.4.2 to v3.4.3.
    Difference
    0.0%
    Check dated 2026-03-06T19:49:12.000Z thumbnail image
  5. Check
    31 days ago
    Change Detected
    Summary
    Update timestamps were added (2026-02-27, 2026-02-26, 2026-02) and older timestamps (2025-12-12, 2025-11-28, 2025-11) were removed from the page.
    Difference
    0.1%
    Check dated 2026-02-27T19:10:03.000Z thumbnail image
  6. Check
    45 days ago
    Change Detected
    Summary
    The site version has been updated from v3.4.1 to v3.4.2; no user-facing changes to the study details page were observed. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.0%
    Check dated 2026-02-13T11:53:11.000Z thumbnail image
  7. Check
    53 days ago
    Change Detected
    Summary
    The change is a backend revision update (v3.4.1 added, v3.4.0 removed) with no visible changes to study content or layout. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.0%
    Check dated 2026-02-05T13:26:06.000Z thumbnail image
  8. Check
    60 days ago
    Change Detected
    Summary
    Added a Show glossary option and updated metadata labels (Last Update Submitted that Met QC Criteria; No FEAR Act Data) with a revision note of v3.4.0, while removing the previous capitalization variant and the No FEAR Act data label.
    Difference
    0.1%
    Check dated 2026-01-29T06:54:16.000Z thumbnail image

Stay in the know with updates to INSIGHT 2: Tepotinib+Osimertinib in MET+ NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the INSIGHT 2: Tepotinib+Osimertinib in MET+ NSCLC Clinical Trial page.